Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683250 | 0.91 | EGFR (0.61) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL30459797 | 0.91 | EGFR (0.61) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18606900 | 0.90 | EGFR (0.60) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18607014 | 0.90 | EGFR (0.49) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18607013 | 0.88 | EGFR (0.45) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18607255 | 0.87 | EGFR (0.48) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18607359 | 0.87 | MKNK2 (0.40) | EGFRCDK2IGF1RDYRK1BDYRK3 | |
| SCHEMBL18607258 | 0.85 | EGFR (0.71) | EGFRIGF1RKCNH2 | |
| SCHEMBL18607119 | 0.82 | EGFR (0.45) | EGFRMKNK2MKNK1KCNH2 | |
| SCHEMBL30393974 | 0.81 | EGFR (0.75) | EGFRCDK2IGF1RDYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885CDK2 247/4885IGF1R 540/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | EGFR 2/4885CDK2 346/4885IGF1R 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.